文献速递骨肿瘤关节外科

在Enneking II/II+III肿瘤切除患者中,同侧股骨头自体骨移植重建是否耐久?至少5年随访

Is Ipsilateral Femoral Head Autograft Reconstruction Durable in Patients Undergoing Enneking II/II+III Tumor Resections at a Minimum 5-year Follow-up?
PubMed 文献 · Clin Orthop Relat Res · 2025-10-13

本研究回顾性分析57例接受Enneking II/II+III骨盆肿瘤切除并部分保留髋臼、采用同侧自体股骨头移植重建的患者,平均随访11年。5年假体移除率5%、翻修率15%,中位MSTS-93评分90%,外展肌切除是功能不良的独立危险因素。作者认为该技术可行,但不推荐用于髋臼完全切除者。

要点

  • 5年累积假体移除率5%(95%CI 1%至13%),翻修率15%(95%CI 7%至25%)。
  • 中位MSTS-93评分为90%(范围57%至100%),外展肌切除与功能不良独立相关(HR 2.9)。
  • 16%患者发生11例并发症,常见为感染、伤口延迟愈合和髋关节脱位。

核心结论

  • 对于部分保留髋臼的Enneking II/II+III骨盆肿瘤患者,同侧自体股骨头移植联合髋关节置换术是一种可行的重建方法。
  • 对于因移植物获取困难、费用或社会/宗教原因无法行肿瘤假体或异体骨重建的患者,可考虑此重建技术。
  • 作者不推荐对髋臼完全切除的患者行此手术,因为自体股骨头移植不足以完全补偿骨缺损。
  • 未来需要更大样本量的研究比较该重建技术与假体或生物重建的优缺点,并明确现有重建技术的患者适应证。

研究设计与样本

  • 回顾性分析2007年1月至2020年6月收治的583例Enneking II/II+III骨盆肿瘤患者,其中187例(32%)行整块切除。
  • 最终纳入57例(10%)行Enneking II/II+III骨盆肿瘤切除、部分保留髋臼并同侧自体股骨头移植重建且随访≥5年的患者。
  • 排除120例(21%)接受其他重建方式者;10例(2%)随访<5年或失访,但部分患者可能在5年内或失访时已出现失败或并发症,故仍纳入分析。
  • 诊断时平均年龄41±13岁,平均随访时间11±3年,男性占51%(29/57)。
  • 最常见病理诊断为骨巨细胞瘤(42%[24/57])和软骨肉瘤(35%[20/57])。

主要发现

  • 末次随访时,84%(48/57)无疾病证据,9%(5/57)带瘤生存,7%(4/57)死于疾病。
  • 2年和5年累积假体移除率分别为2%(95%CI 0.3%至8%)和5%(95%CI 1%至13%)。
  • 2年和5年翻修率分别为10%(95%CI 4%至18%)和15%(95%CI 7%至25%)。
  • 中位MSTS-93评分为90%(范围57%至100%)。
  • 16%(9/57)患者共发生11例并发症,包括5例主要并发症和6例次要并发症;最常见为感染(5%[3/57])、伤口延迟愈合(5%[3/57])和髋关节脱位(4%[2/57])。

关键数值与推荐

  • 功能不良定义为MSTS-93评分<80%。
  • 并发症分为主要和次要并发症,依据是否行非计划再手术。
  • 采用竞争风险估计法估算假体累积移除率和翻修率。
  • 使用术前和术后薄层CT评估髋旋转中心移位。

临床怎么用

  • 作者认为,对于部分保留髋臼的Enneking II/II+III骨盆肿瘤患者,同侧自体股骨头移植联合髋关节置换术是一种可行的重建方法。
  • 作者认为,对于因移植物获取困难、费用或社会/宗教原因无法行肿瘤假体或异体骨重建的患者,可考虑此重建技术。
  • 作者不推荐对髋臼完全切除的患者行此手术。

局限性

  • 10例(2%)患者随访<5年或失访,部分患者可能在5年内或失访时已出现失败或并发症,故仍纳入分析。
  • 未来需要更大样本量的研究比较该重建技术与假体或生物重建的优缺点,并明确现有重建技术的患者适应证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The reconstruction options for Enneking II/II+III pelvic tumors-defined as periacetabular tumor with or without involving the pubis or ischium-remain controversial. Short-term outcomes of ipsilateral femoral head autograft for the reconstruction of acetabular defects have been reported in limited case series studies. However, the long-term stability and complications of this method remain unknown. QUESTIONS/PURPOSES: At a minimum of 5 years of follow-up: (1) What was the graft survival rate in patients who underwent pelvic Enneking II/II+III tumor resections using an ipsilateral autologous femoral head graft for reconstruction? (2) What were the radiologic outcomes? (3) What were the functional outcomes, and what factors were independently associated with poor functional outcomes (Musculoskeletal Tumor Society Score [MSTS]-93 scores < 80%)? (4) What percentage of patients experienced complications, and what were they? METHODS: Between January 2007 and June 2020, we surgically treated 583 patients with Enneking II/II+III pelvic tumors. Ten percent (61 of 583) of patients underwent amputation, 57% (335 of 583) underwent curettage, and the remaining 32% (187 of 583) underwent en bloc resection. During the period in question, we generally used en bloc resection in patients with primary pelvic tumors, invasive benign pelvic tumors, and metastatic pelvic tumors. Patients who underwent en bloc resection were considered potentially eligible for inclusion. This study only included patients who underwent Enneking II/II+III pelvic tumor resections with partial preservation of the acetabulum and ipsilateral femoral head autograft reconstruction and who had 5 years or more of follow-up. Twenty-one percent (120 of 583) of patients were excluded because they received other reconstruction methods. Although 2% (10 of 583) of patients had < 5 years of follow-up or were lost to follow-up, some patients may have experienced failure or complications prior to 5 years or at the time of loss to follow-up. Consequently, these patients should still be included, leaving 10% (57 of 583) of patients for analysis. The mean ± SD age at diagnosis was 41 ± 13 years, and the mean follow-up time was 11 ± 3 years. Fifty-one percent (29 of 57) of patients were men. The most common pathologic diagnoses were giant cell tumor of bone (42% [24 of 57]) and chondrosarcoma (35% [20 of 57]). At the last follow-up, 84% (48 of 57) of patients had no evidence of disease, 9% (5 of 57) were alive with disease, and 7% (4 of 57) died of disease. The graft cumulative removal rate and revision rate were estimated using the competing risk estimator. We used preoperative and postoperative thin-section CT scans to assess the displacement of the hip rotation center. We classified complications into major and minor complications according to whether patients underwent unplanned reoperation. The MSTS-93 score was used to assess functional outcomes. Preoperative and postoperative CT scans were used to assess the displacement distance of the hip rotation center and the femoral neck. Cox regression analysis was used to evaluate risk factors associated with poor postoperative functional scores (MSTS-93 < 80%). RESULTS: The cumulative implant removal rates at 2 years and 5 years were 2% (95% confidence interval [CI] 0.3% to 8%) and 5% (95% CI 1% to 13%), respectively. The revision rates at 2 years and 5 years were 10% (95% CI 4% to 18%) and 15% (95% CI 7% to 25%), respectively. The median (range) MSTS-93 score was 90% (57% to 100%). Sixteen percent (9 of 57) of patients developed a total of 11 complications, including five major complications and six minor complications. The most common complications were infection (5% [3 of 57]), delayed wound healing (5% [3 of 57]), and hip dislocation (4% [2 of 57]). After controlling for potential confounding variables such as gender, age, and previous surgery, we found that abductor muscle resection (cause-specific HR 2.9 [95% CI 1.3 to 6.1]; p = 0.012) was an independent risk factor associated with poor function. CONCLUSION: Among patients with Enneking II/II+III pelvic tumors with partial preservation of the acetabulum, ipsilateral autologous femoral head autografting combined with hip arthroplasty is a viable reconstructive approach. For patients who cannot undergo tumor prosthesis or allograft reconstruction because of difficulties in obtaining grafts, costs, or social and/or religious reasons, this reconstruction technique may be considered. Additionally, we do not recommend this surgery for patients with complete acetabular resection, as autologous femoral head transplantation is insufficient to completely compensate for bone defects. Future studies with larger sample sizes should compare the advantages and disadvantages of this reconstruction technique with prosthetic or biological reconstruction and focus on clarifying the patient indications for existing reconstruction techniques. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Li Z, Fan D, Jin T, et al. Is Ipsilateral Femoral Head Autograft Reconstruction Durable in Patients Undergoing Enneking II/II+III Tumor Resections at a Minimum 5-year Follow-up? Clin Orthop Relat Res. 2025. PMID: 41099542. doi:10.1097/CORR.0000000000003720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。